Imprimis Pharmaceuticals has announced the completion of clinical trials of Impracor, a topical analgesic cream, which delivers a therapeutic dose of the pain-relieving, anti-inflammatory drug ketoprofen.
The study, which was conducted by Novum Pharmaceutical Research Services, measured the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different conditions, including normal activities, heat exposure to the application site and exercising on a treadmill.
The study was carried on 40 healthy volunteers assigned to one of two cohorts 2g or 4g applications.
Imprimis chief executive officer Mark Baum said the firm is happy with the outcome of the important study, which the FDA has mandated as a part of the clinical development of its Impracor topical NSAID program.
"This study provides us with greater confidence in the performance of Impracor as we ready our team for our Phase 3 human clinical trials which are being planned to start in a matter of months," Baum added.
